Afatinib monotherapy in EGFR-mutant lung adenocarcinoma

被引：0
|
作者：
Gilbert, Judith A.
机构：
来源：
LANCET ONCOLOGY | 2013年 / 14卷 / 09期
关键词：
D O I：
10.1016/S1470-2045(13)70346-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E345 / E345
页数：1
相关论文
共 50 条
  • [41] ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
    Gerber, Naamit K.
    Yamada, Yoshiya
    Shi, Weiji
    Zhang, Zhigang
    Riely, Gregory
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Rimner, Andreas
    Wu, Abraham J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S902
  • [42] Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
    Yang, Zhengyu
    Chen, Ya
    Wang, Yanan
    Wang, Shuyuan
    Hu, Minjuan
    Zhang, Bo
    Han, Baohui
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome
    Hissong, Erika
    Baek, Inji
    Costa, Victoria
    Beneck, Debra
    Saxena, Ashish
    Solomon, James P.
    Song, Wei
    [J]. JCO PRECISION ONCOLOGY, 2020, 4 : 818 - 822
  • [44] Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
    Riess, J.
    Kelly, K.
    Schalper, K.
    Shimoda, M.
    Lim, S.
    Monjazeb, A.
    Danenberg, K.
    Moore, E.
    Beckett, L.
    Mack, P.
    Maverakis, E.
    Gandara, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S528 - S528
  • [45] Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
    Gerber, Naamit K.
    Yamada, Yoshiya
    Rimner, Andreas
    Shi, Weiji
    Riely, Gregory J.
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Zhang, Zhigang
    Wu, Abraham J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 322 - 329
  • [46] EGFR-Mutant Lung Cancer: New Drugs
    Sequist, Lecia
    [J]. ONCOLOGIST, 2013, 18 : S1 - S1
  • [47] Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Tsai, Chi-Ren
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Tsai, Meen-Hsin
    Yu, Sung-Liang
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 603 - 610
  • [48] Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation
    Urban, Laszlo
    Doczi, Robert
    Vodicska, Barbara
    Tihanyi, Dora
    Horvath, Magdolna
    Kormos, Dora
    Takacs, Istvan
    Papai-Szekely, Zsolt
    Poka-Farkas, Zsuzsanna
    Varkondi, Edit
    Schwab, Richard
    Hegedus, Csilla
    Valyi-Nagy, Istvan
    Petak, Istvan
    [J]. CLINICAL LUNG CANCER, 2021, 22 (01) : E112 - E115
  • [49] Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
    Tsai, Ming-Ju
    Hung, Jen-Yu
    Ma, Juei-Yang
    Tsai, Yu-Chen
    Wu, Kuan-Li
    Lee, Mei-Hsuan
    Kuo, Chia-Yu
    Chuang, Cheng-Hao
    Lee, Tai-Huang
    Lee, Yen-Lung
    Huang, Chun-Ming
    Shen, Mei-Chiou
    Yang, Chih-Jen
    Chong, Inn-Wen
    [J]. CANCERS, 2023, 15 (07)
  • [50] New Options for EGFR-Mutant Lung Cancer
    不详
    [J]. CANCER DISCOVERY, 2015, 5 (07) : 687 - 688
12345